Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists track medication in Mothers' milk

NCT ID NCT06346288

Summary

This study aimed to measure how much of the IBD medication risankizumab passes into breast milk. It involved about 10 breastfeeding women who were already receiving the drug for their inflammatory bowel disease. Researchers collected breast milk samples over several months to check for the medication's presence and concentration.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shaare Zedek Medical Center /ID# 262738

    Jerusalem, Jerusalem, 91031, Israel

  • UTHealth Women's Research Program - Memorial City /ID# 263939

    Houston, Texas, 77024, United States

  • University of North Carolina at Chapel Hill /ID# 263316

    Chapel Hill, North Carolina, 27514, United States

Conditions

Explore the condition pages connected to this study.